Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kälsch, Julia ^a   Bechmann, Lars P ^a   Heider, Dominik ^b   Best, Jan ^a   Manka, Paul ^a,d   Kälsch, Hagen ^c   Sowa, Jan Peter ^a   Moebus, Susanne ^a   Slomiany, Uta ^a   Jöckel, Karl Heinz ^a   Erbel, Raimund ^c   Gerken, Guido ^a   Canbay, Ali ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES WEIHENSTEPHAN TRIESDORF   (Germany)

^c University Hospital   (Germany)

^d INSTITUTE OF HEPATOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; VITAMIN D;

AGED; BLOOD; BODY MASS; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; FEMALE; HUMAN; LIVER; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADIPONECTIN; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ROC CURVE; VITAMIN D;

EID: 84939419420     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13058     Document Type: Article

References (56)

1. Clark, J. M. & Diehl, A. M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 289, 3000-3004 (2003).
2. Ruhl, C. E. & Everhart, J. E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124, 71-79 (2003).
3. Younossi, Z. M. et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 9, 524-530.e1 (2011).
4. Dietrich, P. & Hellerbrand, C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 28, 637-653 (2014).
5. Vanni, E. et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42, 320-330 (2010).
6. Kim, C. H. & Younossi, Z. M. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75, 721-728 (2008).
7. Verma, S., Jensen, D., Hart, J. & Mohanty, S. R. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 33, 1398-1405 (2013).
8. Torres, D. M. & Harrison, S. A. NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis. Nat Rev Gastroenterol Hepatol 10, 510-511 (2013).
9. Al-hamoudi, W. et al. Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology. Dig. Dis. Sci. 58, 2369-2375 (2013).
10. Park, H. N. et al. Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. Liver Int. 32, 937-944 (2012).
11. Schwimmer, J. B. et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 138, 1357-1364 (2010).
12. Bechmann, L. P. et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 56, 952-964 (2012).
13. Bechmann, L. P. et al. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology 55, 1083-1093 (2012).
14. Wree, A. et al. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metab. Clin. Exp. 63, 1542-1552 (2014).
15. Cheung, O. & Sanyal, A. J. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin. Liver Dis. 28, 351-359 (2008).
16. Albano, E., Mottaran, E., Occhino, G., Reale, E. & Vidali, M. Review article: role of oxidative stress in the progression of nonalcoholic steatosis. Aliment. Pharmacol. Ther. 22 Suppl 2, 71-73 (2005).
17. Day, C. P. From fat to inflammation. Gastroenterology 130, 207-210 (2006).
18. Mitri, J., Muraru, M. D. & Pittas, A. G. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 65, 1005-1015 (2011).
19. Sowa, J.-P. et al. Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS ONE 9, e101444 (2014).
20. Sowa, J.-P. et al. Novel Algorithm for Non-Invasive Assessment of Fibrosis in NAFLD. PLoS ONE 8, e62439 (2013).
21. Ertle, J. M. et al. A combination of α -fetoprotein and des-γ -carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion 87, 121-131 (2013).
22. Bechmann, L. P. et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acidinduced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57, 1394-1406 (2013).
23. Berg, A. H., Combs, T. P., Du, X., Brownlee, M. & Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953 (2001).
24. Cantley, J. The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. Mamm. Genome 25, 442-454 (2014).
25. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845 (1988).
26. Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.-C. & Roudot-Thoraval, F. The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol. 58, 593-608 (2013).
27. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med 346, 1221-1231 (2002).
28. Torres, D. M. & Harrison, S. A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134, 1682-1698 (2008).
29. Müller, G. et al. Regional and neighborhood disparities in the odds of type 2 diabetes: results from 5 population-based studies in Germany (DIAB-CORE consortium). Am. J. Epidemiol. 178, 221-230 (2013).
30. Rathmann, W., Scheidt-Nave, C., Roden, M. & Herder, C. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int 110, 331-337 (2013).
31. Hashimoto, E. & Tokushige, K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol. Res. 42, 1-14 (2012).
32. Siddiqui, M. S. et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 145, 1271-1279.e1-3 (2013).
33. Klein, M. et al. Alanine transferase: An independent indicator of adiposity related comorbidity risk in youth. J Diabetes (2014). doi: 10.1111/1753-0407.12221.
34. Liu, X. et al. Circulating alanine transaminase (ALT) and γ -glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study. Metab. Clin. Exp. 63, 773-782 (2014).
35. Kunutsor, S. K., Apekey, T. A. & Walley, J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. Am. J. Epidemiol. 178, 159-171 (2013).
36. Bradley, R. D. et al. Associations between γ -glutamyltransferase (GGT) and biomarkers of atherosclerosis: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis 233, 387-393 (2014).
37. Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946 (2001).
38. Pham, M. N. et al. Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes Metab. Res. Rev. 29, 166-170 (2013).
39. Stefan, N. et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51, 1884-1888 (2002).
40. Hui, E. et al. Hypoadiponectinemia as an independent predictor for the progression of carotid atherosclerosis: a 5-year prospective study. Metab Syndr Relat Disord 12, 517-522 (2014).
41. Karakurt, F. et al. Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and nondiabetic patients with non-alcoholic fatty liver disease. J. Endocrinol. Invest. 32, 63-68 (2009).
42. Sookoian, S. & Pirola, C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 49, 600-607 (2008).
43. Roberts, C. K. et al. Strength Fitness and Body Weight Status on Markers of Cardiometabolic Health. Med Sci Sports Exerc 47, 1211-8 (2015).
44. Van Marken Lichtenbelt, W. D., Hartgens, F., Vollaard, N. B. J., Ebbing, S. & Kuipers, H. Body composition changes in bodybuilders: a method comparison. Med Sci Sports Exerc 36, 490-497 (2004).
45. Frederiksen, B. N. et al. Association between vitamin D metabolism gene polymorphisms and risk of islet autoimmunity and progression to type 1 diabetes: the diabetes autoimmunity study in the young (DAISY). J. Clin. Endocrinol. Metab. 98, E1845-1851 (2013).
46. Boonchaya-anant, P., Holick, M. F. & Apovian, C. M. Serum 25-hydroxyvitamin D levels and metabolic health status in extremely obese individuals. Obesity (Silver Spring) 22, 2539-2543 (2014).
47. Forouhi, N. G. et al. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia 55, 2173-2182 (2012).
48. Dasarathy, J. et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int. 34, e118-127 (2014).
49. Bril, F. et al. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J. Hepatol. 62, 405-411 (2015).
50. Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 3, 35-42 (2015).
51. Ding, N. et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601-613 (2013).
52. Beilfuss, A. et al. Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently. Gut 64, 791-9 (2015).
53. Tabesh, M., Azadbakht, L., Faghihimani, E., Tabesh, M. & Esmaillzadeh, A. Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial. J. Clin. Endocrinol. Metab. 99, E2485-2493 (2014).
54. Stang, A. et al. Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. Eur. J. Epidemiol. 20, 489-496 (2005).
55. Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am. Heart J. 144, 212-218 (2002).
56. Fithian, W. & Hastie, T. Local case-control sampling: efficient subsampling in imbalanced data sets. Ann Stat 42, 1693-1724 (2014).